P2B001-003, A Phase 3, Twelve-week, Multi-Center, Randomized, Double-Blind, active-controlled, Parallel Group Study to Determine the Safety, Tolerability, and Efficacy of P2B001 Compared to its Individual Components in Subjects with Early Parkinson's Disease

October 03, 2018
https://clinicaltrials.gov/ct2/show/NCT03329508
Parkinson Disease
Principal Investigator: Peter A Le Witt, MD
Parkinson's
Accepting Participants